Skip to Main Content

Author Details

Mireille Goetghebeur
School of Public Health, Universite de Montreal 1
1995
44
23
Jean-Christophe Belisle-Pipon (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36542763HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework.Expert Rev Pharmacoecon Outcomes Res2023
35863618Methodological guidance for incorporating equity when informing rapid-policy and guideline development.J Clin Epidemiol2022
36857208Identifying value arguments and deployment avenues of primary care innovations using a deliberative multidimensional approach.Ann Fam Med2022
35868494Resources supporting trustworthy, rapid and equitable evidence synthesis and guideline development: results from the COVID-19 evidence network to support decision-making (COVID-END).J Clin Epidemiol2022
32610794Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".Int J Health Policy Manag2021
34796318What Makes Artificial Intelligence Exceptional in Health Technology Assessment?Front Artif Intell2021
32206067CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy.Allergy Asthma Clin Immunol2020
31691439Co-construction of health technology assessment recommendations with patients: An example with cardiac defibrillator replacement.Health Expect2020
29270780Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.Adv Ther2018
30455613Can reflective multicriteria be the new paradigm for healthcare decision-making? The EVIDEM journey.Cost Eff Resour Alloc2018
29019295EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE.Int J Technol Assess Health Care2017
30199663The art of priority setting.Lancet2017
28412971Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.BMC Cancer2017
28434413DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.Int J Technol Assess Health Care2017
28324439Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".Pharmacoeconomics2017
27691990TESTING MULTI-CRITERIA DECISION ANALYSIS FOR MORE TRANSPARENT RESOURCE-ALLOCATION DECISION MAKING IN COLOMBIA.Int J Technol Assess Health Care2016
30231761Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study.Ther Innov Regul Sci2016
26547306Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.Pharmacoeconomics2016
25928535Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study.Health Res Policy Syst2015
26152122Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).BMC Health Serv Res2015
24855476Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada.Can J Infect Dis Med Microbiol2014
25904823Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework.Cost Eff Resour Alloc2014
23167310Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.Transfus Med2013
24290340Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers.Int J Technol Assess Health Care2013
21987539Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.Med Decis Making2012
22808944From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking.Cost Eff Resour Alloc2012
22376143Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.Cost Eff Resour Alloc2012
22429601Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review.BMC Infect Dis2012
21214934Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population.BMC Infect Dis2011
22129247Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.BMC Health Serv Res2011
21422818Burden of rotavirus gastroenteritis in the pediatric population in Central and Eastern Europe: serotype distribution and burden of illness.Hum Vaccin2011
20377888Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.Cost Eff Resour Alloc2010
19520205Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.Vaccine2009
19898698Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.Can J Cardiol2009
19531812Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.Can J Clin Pharmacol2009
19102752Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.BMC Health Serv Res2008
18923684Methicillin-resistant Staphylococcus aureus: A public health issue with economic consequences.Can J Infect Dis Med Microbiol2007
16076234Medicare coverage and reimbursement of outpatient prescription drugs in the US: history, recent changes and outlook for the future.Appl Health Econ Health Policy2005
15121312The societal value of universal childhood vaccination.Vaccine2004
12817611Understanding the underlying drivers of inpatient cost growth: a literature review.Am J Manag Care2003
16464197Deep vein thrombosis: cost-effective management of a major health problem.Value Health2000
16674318Towards a European consensus on conducting and reporting health economic evaluations--a report from the ISPOR Inaugural European Conference.Value Health1999
8688193Inhibition of polyphenol oxidase by copper-metallothionein from Aspergillus niger.Phytochemistry1996
8573292Purification and characterization of copper-metallothionein from Aspergillus niger by affinity chromatography.Biotechnol Appl Biochem1995
  • 1 - 44 of 44

Recommended Authors

Nathaniel Hendrix
Harvard T.H. Chan School of Public Health
Career Start Year 2017
Number of shared co-authors 0
Thomas Butt
UCL Institute of Ophthalmology, University College London
Career Start Year 2013
Number of shared co-authors 0
Jeff Round
Institute of Health Economics, University of Alberta
Career Start Year 2010
Number of shared co-authors 0
Dalia Dawoud
Stanford University
Career Start Year 2010
Number of shared co-authors 0
Mike Paulden
School of Public Health, University of Alberta
Career Start Year 2009
Number of shared co-authors 0
Benjamin P Geisler
Massachusetts General Hospital, Harvard Medical School
Career Start Year 2008
Number of shared co-authors 0
James Buchanan
Health Economics Research Centre, University of Oxford
Career Start Year 2007
Number of shared co-authors 0
Nicholas Mitsakakis
Institute of Health Policy Management and Evaluation, University of Toronto
Career Start Year 2003
Number of shared co-authors 0
Victor M Montori
Knowledge and Evaluation Research Unit in Endocrinology (KER_Endo), Mayo Clinic
Career Start Year 1998
Number of shared co-authors 1
Manuel Ridao
Instituto Aragones de Ciencias de la Salud (IIS Aragon)
Career Start Year 1997
Number of shared co-authors 0
Emily Beth Devine
University of Washington
Career Start Year 1997
Number of shared co-authors 0
Maarten J IJzerman
Technical Medical Centre, University of Twente
Career Start Year 1997
Number of shared co-authors 1
Sarah Wordsworth
Health Economics Research Centre, University of Oxford
Career Start Year 1997
Number of shared co-authors 0
Christopher McCabe
Queens University Belfast
Career Start Year 1996
Number of shared co-authors 0
Andrew Walker
University of California San Diego
Career Start Year 1995
Number of shared co-authors 0
George Tomlinson
University Health Network
Career Start Year 1994
Number of shared co-authors 0
David O Meltzer
The University of Chicago
Career Start Year 1993
Number of shared co-authors 0
Ben van Hout
University of Sheffield
Career Start Year 1993
Number of shared co-authors 0
Jason N Doctor
University of Southern California
Career Start Year 1992
Number of shared co-authors 0
David L Veenstra
University of Washington
Career Start Year 1992
Number of shared co-authors 1
Mark S Roberts
School of Public Health, University of Pittsburgh
Career Start Year 1988
Number of shared co-authors 0
Sean Tunis
Center for Evaluation of Value and Risk in Health, Tufts Medical Center
Career Start Year 1987
Number of shared co-authors 0
Joel Tsevat
Dell Medical School, University of Texas at Austin
Career Start Year 1987
Number of shared co-authors 0
Frank A Sonnenberg
Robert Wood Johnson Medical School, The State University of New Jersey
Career Start Year 1986
Number of shared co-authors 1
John B Wong
Tufts University School of Medicine
Career Start Year 1986
Number of shared co-authors 0
Benjamin Djulbegovic
Medical University of South Carolina
Career Start Year 1985
Number of shared co-authors 1
Wendy J Ungar
The Hospital for Sick Children
Career Start Year 1984
Number of shared co-authors 0
Theodore G Ganiats
university of california san diego
Career Start Year 1983
Number of shared co-authors 0
Mark Helfand
Oregon Health & Science University
Career Start Year 1983
Number of shared co-authors 0
Harold P Lehmann
Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 0

Collaborators

James G Dolan
University of Rochester
Co-authored papers 2
Isabelle Ganache
Institut National D'Excellence en Sante et en Services Sociaux (INESSS)
Co-authored papers 1
Marie-Christine Roy
Universite de Montreal.
Co-authored papers 1
Vincent Couture
Laval University
Co-authored papers 1
Per Olav Vandvik
Lovisenberg Diaconal Hospital
Co-authored papers 1
Ivan Glenn Cohen
Petrie-Flom Center for Health Law Policy, Harvard University
Co-authored papers 1
Jean-Christophe Belisle-Pipon (CM4AI)
Simon Fraser University
Co-authored papers 1
Release 1.2